Table 3 |
|||||||||
|
Risk of lung cancer in association with aspirin use – Roswell Park Cancer Institute, 1982–1998. |
|||||||||
|
Total Sample |
Females |
Males |
|||||||
|
|
|
|
|||||||
|
Cases (n = 868) |
Controls (n = 935) |
Adjusted OR1 (95% CI) |
Cases (n = 335) |
Controls (n = 358) |
Adjusted OR1 (95% CI) |
Cases (n = 533) |
Controls (n = 577) |
Adjusted OR1 (95% CI) |
|
|
|
|||||||||
|
Non-User |
747 |
768 |
1.0 |
299 |
306 |
1.0 |
448 |
462 |
1.0 |
|
Regular User2 |
121 |
167 |
0.57 (0.41–0.78) |
36 |
52 |
0.52 (0.29–0.95) |
85 |
115 |
0.62 (0.43–0.90) |
|
1–6 tablets/week |
26 |
41 |
0.53 (0.28–0.99) |
9 |
26 |
0.17 (0.05–0.50) |
17 |
15 |
1.01 (0.46–2.59) |
|
7+ tablets/week |
95 |
126 |
0.58 (0.41–0.82) |
27 |
26 |
0.88 (0.43–1.79) |
68 |
100 |
0.56 (0.37–0.83) |
|
p = 0.04 |
p = 0.19 |
p = 0.006 |
|||||||
|
1–10 years of use |
90 |
126 |
0.56 (0.39–0.79) |
23 |
38 |
0.42 (0.21–0.86) |
67 |
88 |
0.65 (0.43–0.98) |
|
11+ years of use |
31 |
41 |
0.61 (0.34–1.09) |
13 |
14 |
0.88 (0.30–2.55) |
18 |
27 |
0.53 (0.26–1.10) |
|
p = 0.06 |
p = 0.11 |
p = 0.01 |
|||||||
|
1–10 tablet years3 |
84 |
106 |
0.63 (0.44–0.92) |
20 |
30 |
0.47 (0.22–0.99) |
64 |
76 |
0.73 (0.48–1.12) |
|
11+ tablet years |
37 |
61 |
0.45 (0.27–0.77) |
16 |
22 |
0.61 (0.24–1.54) |
21 |
39 |
0.40 (0.21–0.78) |
|
p < 0.001 |
p = 0.07 |
p = 0.004 |
|||||||
|
|
|||||||||
|
1 Odds ratio adjusted for age, education, and packyears of cigarettes 2 Regular use was defined as self-reported use at least once a week for at least one year 3 Tablets per day × years of use |
|||||||||
|
Moysich et al. BMC Cancer 2002 2:31 doi:10.1186/1471-2407-2-31 |
|||||||||
